Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 48

1.

Extensive Pyoderma Gangrenosum Associated With Granulomatosis With Polyangiitis With Both Responsive to Rituximab.

Murthy RK, Jackson J, Chatham WW, Sami N.

J Clin Rheumatol. 2016 Oct;22(7):393-5. doi: 10.1097/RHU.0000000000000447. No abstract available.

PMID:
27660945
2.
3.

A Heterozygous RAB27A Mutation Associated with Delayed Cytolytic Granule Polarization and Hemophagocytic Lymphohistiocytosis.

Zhang M, Bracaglia C, Prencipe G, Bemrich-Stolz CJ, Beukelman T, Dimmitt RA, Chatham WW, Zhang K, Li H, Walter MR, De Benedetti F, Grom AA, Cron RQ.

J Immunol. 2016 Mar 15;196(6):2492-503. doi: 10.4049/jimmunol.1501284. Epub 2016 Feb 15.

4.

Interleukin-1 Receptor Blockade Is Associated With Reduced Mortality in Sepsis Patients With Features of Macrophage Activation Syndrome: Reanalysis of a Prior Phase III Trial.

Shakoory B, Carcillo JA, Chatham WW, Amdur RL, Zhao H, Dinarello CA, Cron RQ, Opal SM.

Crit Care Med. 2016 Feb;44(2):275-81. doi: 10.1097/CCM.0000000000001402.

5.

Convergent Validity of New Disease Assessment Instruments (Dai) In Systemic Lupus Erythematosus (Sle) In Relation to Sledai-2k.

Narayanan S, Collins CE, Busch HM, Gaylis N, Hautamaki E, Chatham WW.

Value Health. 2015 Nov;18(7):A677. doi: 10.1016/j.jval.2015.09.2004. Epub 2015 Oct 20. No abstract available.

6.

Vasculitis related to viral and other microbial agents.

Teng GG, Chatham WW.

Best Pract Res Clin Rheumatol. 2015 Apr;29(2):226-43. doi: 10.1016/j.berh.2015.05.007. Epub 2015 Jun 11. Review.

PMID:
26362741
7.

Does Viral Hemorrhagic Fever Represent Reactive Hemophagocytic Syndrome?

Cron RQ, Behrens EM, Shakoory B, Ramanan AV, Chatham WW.

J Rheumatol. 2015 Jul;42(7):1078-80. doi: 10.3899/jrheum.150108. No abstract available.

PMID:
26136549
8.

Randomized, Double-Blind, Placebo-Controlled Trial of the Effect of Vitamin D3 on the Interferon Signature in Patients With Systemic Lupus Erythematosus.

Aranow C, Kamen DL, Dall'Era M, Massarotti EM, Mackay MC, Koumpouras F, Coca A, Chatham WW, Clowse ME, Criscione-Schreiber LG, Callahan S, Goldmuntz EA, Keyes-Elstein L, Oswald M, Gregersen PK, Diamond B.

Arthritis Rheumatol. 2015 Jul;67(7):1848-57. doi: 10.1002/art.39108.

9.

Cell-bound complement activation products in systemic lupus erythematosus: comparison with anti-double-stranded DNA and standard complement measurements.

Putterman C, Furie R, Ramsey-Goldman R, Askanase A, Buyon J, Kalunian K, Chatham WW, Massarotti E, Kirou K, Jordan N, Blanco I, Weinstein A, Chitkara P, Manzi S, Ahearn J, O'Malley T, Conklin J, Ibarra C, Barken D, Dervieux T.

Lupus Sci Med. 2014 Oct 1;1(1):e000056. doi: 10.1136/lupus-2014-000056. eCollection 2014.

10.

Disease control and safety of belimumab plus standard therapy over 7 years in patients with systemic lupus erythematosus.

Ginzler EM, Wallace DJ, Merrill JT, Furie RA, Stohl W, Chatham WW, Weinstein A, McKay JD, McCune WJ, Zhong ZJ, Freimuth WW, Petri MA; LBSL02/99 Study Group.

J Rheumatol. 2014 Feb;41(2):300-9. doi: 10.3899/jrheum.121368. Epub 2013 Nov 1.

11.

Genome-wide DNA methylation analysis of systemic lupus erythematosus reveals persistent hypomethylation of interferon genes and compositional changes to CD4+ T-cell populations.

Absher DM, Li X, Waite LL, Gibson A, Roberts K, Edberg J, Chatham WW, Kimberly RP.

PLoS Genet. 2013;9(8):e1003678. doi: 10.1371/journal.pgen.1003678. Epub 2013 Aug 8.

12.

Measurement of cell-bound complement activation products enhances diagnostic performance in systemic lupus erythematosus.

Kalunian KC, Chatham WW, Massarotti EM, Reyes-Thomas J, Harris C, Furie RA, Chitkara P, Putterman C, Gross RL, Somers EC, Kirou KA, Ramsey-Goldman R, Hsieh C, Buyon JP, Dervieux T, Weinstein A.

Arthritis Rheum. 2012 Dec;64(12):4040-7. doi: 10.1002/art.34669.

13.

Device for carrying blood samples at 37°C for cryoglobulin test.

Nahm MH, Chatham WW, Benjamin WH Jr.

Clin Vaccine Immunol. 2012 Sep;19(9):1555-6. doi: 10.1128/CVI.00295-12. Epub 2012 Jul 18.

14.

Effect of belimumab on vaccine antigen antibodies to influenza, pneumococcal, and tetanus vaccines in patients with systemic lupus erythematosus in the BLISS-76 trial.

Chatham WW, Wallace DJ, Stohl W, Latinis KM, Manzi S, McCune WJ, Tegzová D, McKay JD, Avila-Armengol HE, Utset TO, Zhong ZJ, Hough DR, Freimuth WW, Migone TS; BLISS-76 Study Group.

J Rheumatol. 2012 Aug;39(8):1632-40. Epub 2012 Jun 15.

15.

2012 update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis.

Singh JA, Furst DE, Bharat A, Curtis JR, Kavanaugh AF, Kremer JM, Moreland LW, O'Dell J, Winthrop KL, Beukelman T, Bridges SL Jr, Chatham WW, Paulus HE, Suarez-Almazor M, Bombardier C, Dougados M, Khanna D, King CM, Leong AL, Matteson EL, Schousboe JT, Moynihan E, Kolba KS, Jain A, Volkmann ER, Agrawal H, Bae S, Mudano AS, Patkar NM, Saag KG.

Arthritis Care Res (Hoboken). 2012 May;64(5):625-39. doi: 10.1002/acr.21641. Review. No abstract available.

16.

Belimumab reduces autoantibodies, normalizes low complement levels, and reduces select B cell populations in patients with systemic lupus erythematosus.

Stohl W, Hiepe F, Latinis KM, Thomas M, Scheinberg MA, Clarke A, Aranow C, Wellborne FR, Abud-Mendoza C, Hough DR, Pineda L, Migone TS, Zhong ZJ, Freimuth WW, Chatham WW; BLISS-52 Study Group; BLISS-76 Study Group.

Arthritis Rheum. 2012 Jul;64(7):2328-37. doi: 10.1002/art.34400.

17.

A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus.

Furie R, Petri M, Zamani O, Cervera R, Wallace DJ, Tegzová D, Sanchez-Guerrero J, Schwarting A, Merrill JT, Chatham WW, Stohl W, Ginzler EM, Hough DR, Zhong ZJ, Freimuth W, van Vollenhoven RF; BLISS-76 Study Group.

Arthritis Rheum. 2011 Dec;63(12):3918-30. doi: 10.1002/art.30613.

18.

B lymphocytes are resistant to death receptor 5-induced apoptosis.

Crowder RN, Zhao H, Chatham WW, Zhou T, Carter RH.

Clin Immunol. 2011 Apr;139(1):21-31. doi: 10.1016/j.clim.2010.12.006. Epub 2011 Jan 28.

19.

Novel evidence-based systemic lupus erythematosus responder index.

Furie RA, Petri MA, Wallace DJ, Ginzler EM, Merrill JT, Stohl W, Chatham WW, Strand V, Weinstein A, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1143-51. doi: 10.1002/art.24698.

20.

A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus.

Wallace DJ, Stohl W, Furie RA, Lisse JR, McKay JD, Merrill JT, Petri MA, Ginzler EM, Chatham WW, McCune WJ, Fernandez V, Chevrier MR, Zhong ZJ, Freimuth WW.

Arthritis Rheum. 2009 Sep 15;61(9):1168-78. doi: 10.1002/art.24699.

Supplemental Content

Loading ...
Support Center